Comparative Pharmacology
Head-to-head clinical analysis: FREAMINE III 3 W ELECTROLYTES versus FREAMINE III 8 5 W ELECTROLYTES.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FREAMINE III 3 W ELECTROLYTES versus FREAMINE III 8 5 W ELECTROLYTES.
FREAMINE III 3% W/ ELECTROLYTES vs FREAMINE III 8.5% W/ ELECTROLYTES
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Provides essential and non-essential amino acids for protein synthesis, maintaining nitrogen balance, and supporting metabolic functions. Electrolytes help maintain acid-base balance and osmotic pressure.
FREAMINE III 8.5% W/ ELECTROLYTES is a crystalline amino acid solution that provides essential and non-essential amino acids for protein synthesis, promoting nitrogen balance and tissue maintenance in patients unable to tolerate oral/enteral nutrition.
Administered intravenously. Typical adult dose: 500-1000 mL/day (15-30 g amino acids) infused at a rate not exceeding 0.1 g/kg/hour. Frequency: continuous or intermittent infusion as part of parenteral nutrition.
Intravenous infusion: 1.0-1.5 g amino acids/kg/day (equivalent to 12-18 mL/kg/day of 8.5% solution). Administer via central or peripheral line. Typical adult dose: 500-1000 mL/day infused at 125-200 mL/hour.
None Documented
None Documented
Variable; based on individual amino acid components (alanine ~2.3h, glycine ~1.5h, etc.); clinical context: continuous infusion achieves steady state within 8-12h
Not applicable as a composite mixture; individual amino acid half-lives vary from minutes to hours. Clinical context: continuous infusion used for metabolic support.
Renal excretion of amino acid nitrogen as urea (85-90%) and other nitrogenous wastes; minimal biliary/fecal (<5%)
Renal (primarily as urea and ammonia); 100% of infused amino acids are metabolized or excreted renally. Fecal excretion negligible.
Category C
Category C
Parenteral nutrition amino acid
Parenteral nutrition amino acid